NIBR Model Improves Novartis Early Pipeline Success Rate

Eight years after Novartis AG launched the Novartis Institutes for Biomedical Research under Harvard Medical School cardiologist Mark Fishman and let him design a novel strategy for vetting early-stage projects, the company's Phase II success rate for new molecular entities has doubled.